Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,115 Million (Small Cap)
43.00
NA
0.00%
-0.49
6.55%
3.14
Revenue and Profits:
Net Sales:
105 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.64%
0%
0.64%
6 Months
1.13%
0%
1.13%
1 Year
-29.22%
0%
-29.22%
2 Years
7.57%
0%
7.57%
3 Years
-30.63%
0%
-30.63%
4 Years
-44.1%
0%
-44.1%
5 Years
3.82%
0%
3.82%
C-RAD AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.21%
EBIT Growth (5y)
82.28%
EBIT to Interest (avg)
29.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.49
Sales to Capital Employed (avg)
1.47
Tax Ratio
39.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
32.53%
ROE (avg)
10.39%
Valuation key factors
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
3.22
EV to EBIT
13.38
EV to EBITDA
11.95
EV to Capital Employed
5.13
EV to Sales
2.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
38.32%
ROE (Latest)
7.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
105.20
129.40
-18.70%
Operating Profit (PBDIT) excl Other Income
12.20
20.00
-39.00%
Interest
3.30
4.40
-25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.00
10.60
-62.26%
Operating Profit Margin (Excl OI)
92.20%
147.60%
-5.54%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -18.70% vs 42.83% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -62.26% vs 96.30% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
469.00
424.60
10.46%
Operating Profit (PBDIT) excl Other Income
74.10
53.60
38.25%
Interest
0.30
0.40
-25.00%
Exceptional Items
0.10
0.20
-50.00%
Consolidate Net Profit
56.40
35.50
58.87%
Operating Profit Margin (Excl OI)
149.80%
115.40%
3.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.46% vs 40.92% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 58.87% vs 373.33% in Dec 2023
About C-RAD AB 
C-RAD AB
Pharmaceuticals & Biotechnology
C-Rad AB is a Sweden-based holding company active in the medical equipment industry. It offers products and solutions to the radiation therapy market. C-Rad AB is the parent company within the C-Rad group (the Group). The Group provides such products, as Sentinel, a surface contour laser scanning system for patient positioning, monitoring and gating applications; Catalyst, a surface scanning system, which allows the identification and tracking of markers, and GEMini, a system based on a gaseous detector using metal converters interleaved with Gas Electron Multipliers (GEMs), as well as other products. The Company operates through several subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB, C-RAD Innovation AB and Cyrpa International Sprl. The Company’s largest shareholder is Inter Life Science AB.
Company Coordinates 
Company Details
Bredgrand 18 , UPPSALA None : 753 20
Registrar Details






